Mast Therapeutics, Inc.

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for heart failure, a condition with a high unmet need for innovative treatment options.

For investor information, please view our Investors page.